Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00130156
Status:
COMPLETED
Last Update Posted:
2013-05-14
First Post:
2005-08-12
Brief Title:
Effects of Combination Therapy With Alpha-1 Blocker Bunazosin or Doxazosin in the Treatment of Patients With Mild to Moderate Essential Hypertension
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
Effects of Combination Therapy With an α1-blocker Sustained-release Preparation of Bunazosin or Doxazosin in Inadequate Responders to an Angiotensin II Antagonist Valsartan in the Treatment of Patients With Mild to Moderate Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome
Detailed Description:
This clinical study will comprise a 1 to 2-week washout period a 5-week mono therapy period with Angiotensinâ…ˇantagonist and an 8-week alpha blocker add-on treatment period Total study period will be 15 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None